RedHill: Clinical Trial Application Approved In Russia For Phase 2/3 Study With Opaganib

(RTTNews) - RedHill Biopharma Ltd. (RDHL) received approval in Russia for a phase 2/3 study evaluating opaganib in patients hospitalized with severe SARS-CoV-2 infection and pneumonia. The multi-center, randomized, double-blind, parallel-arm, placebo-controlled phase 2/3 study is set to enroll up to 270 patients with severe COVID-19 pneumonia requiring hospitalization and treatment with supplemental oxygen.

The study was also recently approved in the UK and a similar application is under review in Italy. The company also has received approval from the Israeli Ministry of Health to initiate a study evaluating opaganib in up to 50 patients with severe COVID-19 infection and pneumonia.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.